Anuh Pharma Limited has informed the Exchange regarding the approval of Un-audited Financial Results and appointment of Chief Marketing Officer during the Board meeting held on August 08, 2025.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma's Board, on August 8, 2025, approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025) and appointed Mr. Vinayak Shenoy as Chief Marketing Officer effective August 11, 2025. Revenue from operations rose sharply to Rs. 18,647.94 lakhs, up about 35% from Rs. 13,790.83 lakhs in the same quarter last year. However, profit after tax fell to Rs. 830.12 lakhs from Rs. 950.91 lakhs, a decline of roughly 13% YoY. EBITDA margin also compressed to 7.34% from 10.36% a year ago, indicating pressure on profitability despite the strong top-line growth. Basic EPS stood at Rs. 1.66 versus Rs. 1.90 in Q1 FY25. The statutory auditors (Jayantilal Thakkar & Co.) issued an unqualified limited review report on the results.
Strong revenue growth is a positive signal, but shrinking margins and a dip in profit may weigh on the stock in the short term. The new CMO appointment signals a focus on expanding global sales in APIs and intermediates, which could support long-term growth.